The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazoline1 receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.

The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazoline1 receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.

The disclosure provides oral compositions including at least one active ingredient and a polymeric component, the oral compositions having a moisture content of at least about 10% by weight, based on total weight of the oral composition. The polymeric component includes a natural gum, a food grade polymer, or a combination thereof. The natural gum may be a non-galactomannan polysaccharide; a galactomannan polysaccharide selected from fenugreek gum, tara gum, locust bean gum, cassia gum, and combinations thereof; or a combination of guar gum and a second natural gum. The food grade polymer may be selected from proteins, synthetic polymers, non-cellulosic polysaccharides which are not natural gums, and combinations thereof.

The disclosure provides oral compositions including at least one active ingredient and a polymeric component, the oral compositions having a moisture content of at least about 10% by weight, based on total weight of the oral composition. The polymeric component includes a natural gum, a food grade polymer, or a combination thereof. The natural gum may be a non-galactomannan polysaccharide; a galactomannan polysaccharide selected from fenugreek gum, tara gum, locust bean gum, cassia gum, and combinations thereof; or a combination of guar gum and a second natural gum. The food grade polymer may be selected from proteins, synthetic polymers, non-cellulosic polysaccharides which are not natural gums, and combinations thereof.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

Embodiments herein relate to compositions herein can include one or more of a tomato extract, a rhubarb extract, a garlic extract, a cashew shell composition, and a saponin composition, wherein the composition prevents or reduces methanogenesis in animals. Embodiments herein also relate to compositions including one or more of glycoalkaloids, saponins, anthraquinones, anacardic acid, and allicin and methods for using the same for mitigating methanogenesis in animals. In an embodiment, a composition can include glycoalkaloids, such as α-tomatine, that can prevent methanogenesis. In an embodiment, a method of processing animal feed is included. In an embodiment, a method of treating an animal to reduce methanogenesis is included. Other embodiments are also included herein.

Embodiments herein relate to compositions herein can include one or more of a tomato extract, a rhubarb extract, a garlic extract, a cashew shell composition, and a saponin composition, wherein the composition prevents or reduces methanogenesis in animals. Embodiments herein also relate to compositions including one or more of glycoalkaloids, saponins, anthraquinones, anacardic acid, and allicin and methods for using the same for mitigating methanogenesis in animals. In an embodiment, a composition can include glycoalkaloids, such as α-tomatine, that can prevent methanogenesis. In an embodiment, a method of processing animal feed is included. In an embodiment, a method of treating an animal to reduce methanogenesis is included. Other embodiments are also included herein.

A supplement formulation including a combination of vitamins, minerals, amino acids, and stimulants, and a delivery method and device for said supplement formulation. Caffeine is present in the supplement formulation in an amount of about 40-60 mg/ml, of which about 15-30 mg/ml is caffeine from coffee beans and about 15-30 mg/ml is caffeine from green tea extract. About 5-20 mg/ml caffeine from guarana seed extract may also be present. Such a delivery device provides the supplement to a mouth/throat area of a user where it is readily absorbed in the mouth/throat area of the user or ingested by the user.